← Back to Search

Tezepelumab for Asthma (VECTOR Trial)

Phase 3
Waitlist Available
Research Sponsored by AstraZeneca
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 0, week 12, week 16 and week 28
Awards & highlights

VECTOR Trial Summary

This study is evaluating whether a drug called tezepelumab can improve the immune response to a flu vaccine.

Eligible Conditions
  • Asthma

VECTOR Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 0, week 12, week 16 and week 28
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 0, week 12, week 16 and week 28 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage of Patients With Post-vaccination Strain-specific Antibody Response at Week 16 With Antibody Response Defined as a ≥ 4-fold Rise in HAI Antibody Titer
Percentage of Patients With Post-vaccination Strain-specific Antibody Response at Week 16 With Antibody Response Defined as a ≥ 4-fold Rise in MN Antibody Titer
Percentage of Patients With Post-vaccination Strain-specific HAI Antibody Titer ≥ 40
+5 more
Secondary outcome measures
Immunogenicity
Serum Tezepelumab Concentrations

Side effects data

From 2020 Phase 3 trial • 150 Patients • NCT03406078
16%
Nasopharyngitis
12%
Upper respiratory tract infection
8%
Asthma
8%
Bronchitis bacterial
5%
Myalgia
5%
Bronchitis
5%
Oral candidiasis
4%
Headache
4%
Fall
3%
Hypertension
1%
Cardiac failure
1%
Cataract
1%
Supraventricular tachycardia
1%
Inguinal hernia
1%
Intervertebral discitis
1%
Pneumonia
1%
Septic shock
1%
Incisional hernia
1%
Arthralgia
1%
Invasive breast carcinoma
1%
Acute kidney injury
1%
Nephrolithiasis
1%
Sinusitis
1%
Cardiac arrest
100%
80%
60%
40%
20%
0%
Study treatment Arm
Tezepelumab
Placebo

VECTOR Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: TezepelumabExperimental Treatment1 Intervention
Participants will be randomized to receive tezepelumab 210 mg administered at Weeks 0, 4, 8 and 12. Participants will also receive a single dose of inactivated quadrivalent seasonal influenza vaccine intramuscularly at Week 12, prior to the fourth dose of study intervention.
Group II: Placebo to TezepelumabPlacebo Group1 Intervention
Participants will be randomized to receive placebo SC Q4W, administered at Weeks 0, 4, 8 and 12. Participants will also receive a single dose of inactivated quadrivalent seasonal influenza vaccine intramuscularly at Week 12, prior to the fourth dose of study intervention.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tezepelumab
2018
Completed Phase 3
~2120

Find a Location

Who is running the clinical trial?

AmgenIndustry Sponsor
1,369 Previous Clinical Trials
1,377,476 Total Patients Enrolled
22 Trials studying Asthma
6,039 Patients Enrolled for Asthma
AstraZenecaLead Sponsor
4,256 Previous Clinical Trials
288,593,566 Total Patients Enrolled
328 Trials studying Asthma
639,564 Patients Enrolled for Asthma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
Texas
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma
2021. "Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05062759.
~20 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top